Financial Performance - Stratasys reported a loss of 4 cents per share in Q2 2024, in line with the Zacks Consensus Estimate, compared to non-GAAP earnings of 4 cents per share in the year-ago quarter [1] - Quarterly revenues declined 13.6% YoY to $138 million, missing the consensus mark by 6.78%, partially due to divestitures and unfavorable foreign currency exchange rates [1] - Non-GAAP gross profit fell 9.8% YoY to $67.7 million, while the non-GAAP gross margin expanded 50 bps to 49% [2] - Non-GAAP operating expenses decreased 2.2% YoY to $70.9 million, resulting in a non-GAAP operating loss of $3.2 million, compared to a profit of $5 million in the year-ago quarter [2] - Adjusted EBITDA plunged 78.3% YoY to $2.3 million [2] Segment Performance - Product revenues declined 14.2% YoY to $93.6 million, with System revenues plunging 40% YoY to $29 million, while Consumables revenues increased 6.3% YoY to $64.6 million [2] - Services revenues declined 12.2% YoY to $44.4 million, with Customer Support revenues advancing 3.8% YoY to $30.5 million [2] Strategic Developments - Stratasys solidified a partnership with AM Craft to support additive manufacturing of EASA-certified aircraft sustainment parts, opening new opportunities in the aviation sector [3] - The company launched new products, including SAF High-Def printing capabilities, H350 version 1.5, and SAF Polypropylene material, expanding manufacturing applications and use cases [3] - Stratasys software offerings, including GrabCAD Print Pro and GrabCAD Streamline Pro, showed strong demand, with Print Pro expanding to PolyJet users and Streamline Pro gaining traction [3] Balance Sheet & Cash Flow - Stratasys ended Q2 with cash and short-term deposits of $150.9 million, down from $161.1 million at the end of the previous quarter [4] - The company reported a negative operating cash flow of $2.4 million, a significant decline from the positive operating cash flow of $7.3 million in the previous quarter [4] 2024 Outlook - Management lowered 2024 revenue projections to $570-$580 million, down from the previous forecast of $630-$645 million [5][6] - Non-GAAP earnings per share are now forecasted at 1-5 cents, compared to the previous range of 12-19 cents [5][6] - Gross margins are expected to be between 48.7% and 49%, down from the previous range of 49%-49.5% [5][6] - Non-GAAP operating margin is projected at 0.5%-1%, compared to the previous range of 2.5%-3.5% [5][6] - Operating expenses are estimated at $276-$278 million, down from the previous range of $292-$297 million [5][6] - Adjusted EBITDA is projected at $24-$27 million, down from the previous range of $40-$45 million [5][6] Stock Performance - Stratasys' shares have plunged 51.5% year-to-date, underperforming the Zacks Computer & Technology sector's rise of 20.3% [6]

Stratasys Ltd. SSYS reported worse-than-expected second-quarter sales and cut its FY24 guidance on Thursday.Stratasys reported fiscal second-quarter 2024 revenue of $138.04million, missing the analyst consensus estimate of $146.34 million. Adjusted EPS loss of 4 cents beat the analyst consensus estimate of 5 cent loss.The company shared plans to downsize its workforce by 15% by 2024 end to save $40 million in annual cost beginning in the first quarter of 2025, along with annualized EBITDA margins of 8%.Stra ...

Stratasys stock is 3D printing nothing but losses these days.Stratasys (SSYS -14.71%) stock fell 14.9% through 12:05 p.m. on mixed earnings on Thursday.Wall Street analysts had forecast the 3D printing company would lose $0.05 per share in the second quarter, and the good news is that Stratasys beat that estimate -- losing "only" $0.04. The bad news is that Stratasys fell well short of Street forecasts for $146.3 million in Q2 sales, reporting only $138 million. Stratasys' Q2 earningsThis news gets worse. T ...

STRATASYS LTD. Exhibit 99.1 CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 (UNAUDITED) 1 STRATASYS LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited) INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024 (UNAUDITED) | Item | Page | | --- | --- | | Consolidated Balance Sheets | 3 | | Consolidated Statements of Operations and Comprehensive Loss | 4 | | Consolidated Statements of Chan ...

Financial Data and Key Metrics Changes - Consolidated revenue for Q2 2024 was $138 million, down 13.6% compared to Q2 2023 [28] - Product revenue decreased by 14.2% to $93.6 million from $109.1 million year-over-year [28] - System revenue fell by 40% to $29 million compared to $48.3 million in the same period last year [28] - Consumables revenue grew by 6.3% to $64.6 million, indicating strong utilization of existing systems [29] - GAAP gross margin improved to 43.8% from 41.5% year-over-year, while non-GAAP gross margin increased to 49% from 48.5% [30] - GAAP net loss for the quarter was $25.7 million, or $0.36 per diluted share, compared to a net loss of $38.6 million, or $0.56 per diluted share in the same period last year [32] Business Line Data and Key Metrics Changes - Consumables revenue growth reflects strong utilization rates of existing systems, primarily from FDM technologies [8][29] - Service revenue, including Stratasys Direct, decreased by 12.2% to $44.4 million compared to $50.7 million in the same period last year [29] - Customer support revenue within service revenue was down 3.8% year-over-year [29] Market Data and Key Metrics Changes - The company noted ongoing softness in hardware sales due to high interest rates and macroeconomic uncertainty affecting capital equipment spending [8] - The utilization of consumables is expected to remain resilient despite hardware sales weakness, as the installed base continues to be well utilized [29] Company Strategy and Development Direction - The company is committed to innovation in materials and workflow to address adoption opportunities, focusing on key end-use applications [9] - A strategic review led to restructuring actions expected to produce approximately $40 million in annual cost savings starting Q1 2025 [22] - The company aims to strengthen market penetration by helping customers overcome barriers to additive manufacturing adoption [24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about hardware sales growth in the second half of 2024 due to an improved pipeline and expected higher government sales [33] - The ongoing macroeconomic challenges are anticipated to persist, causing delays in purchases and longer sales cycles [33] - Management highlighted strong utilization rates and engagement levels despite current purchase constraints, indicating potential for future growth [26] Other Important Information - The company plans to relocate its US headquarters to enhance collaboration and efficiency [18] - New product introductions include the H350 version 1.5 and the J5 Digital Anatomy 3D Printer, aimed at expanding manufacturing applications [12][13] Q&A Session Summary Question: Insights from the strategic alternatives process - Management learned the importance of investing in strategies and focusing on unique assets to create shareholder value [39] Question: Quantifying pent-up demand - Management refrained from quantifying demand but noted increased utilization rates and a shift towards manufacturing applications [40][41] Question: Gross margin outlook for the second half - Management indicated that gross margin expectations are influenced by a mix of hardware, consumables, and services, maintaining a solid outlook [44][45] Question: Impact of workforce reduction on revenue growth - Management emphasized that the restructuring is strategy-led and focused on proven use cases to maintain growth while ensuring profitability [56][63] Question: Utilization of machines sold during COVID - Management noted that while tracking utilization is challenging, material sales growth indicates a shift towards manufacturing and tooling applications [70] Question: Revenue expectations and restructuring savings - Management clarified that the expected 8% EBITDA margin is based on mid-range annual guidance, with savings from restructuring to be realized over time [74]

Company Performance - Stratasys reported a quarterly loss of $0.04 per share, matching the Zacks Consensus Estimate, compared to earnings of $0.04 per share a year ago [1] - The company posted revenues of $138.04 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 6.78%, and down from $159.75 million year-over-year [1] - Over the last four quarters, Stratasys has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [1] Stock Movement and Outlook - Stratasys shares have declined approximately 46.2% since the beginning of the year, contrasting with the S&P 500's gain of 17.2% [2] - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call [2][3] Earnings Estimates and Industry Context - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $165.07 million, and for the current fiscal year, it is $0.14 on revenues of $631.49 million [4] - The Zacks Industry Rank for Computer - Peripheral Equipment is in the top 4% of over 250 Zacks industries, indicating a favorable outlook for the sector [5]

Stratasys (SSYS) is slated to release second-quarter 2024 results on Aug. 29.The Zacks Consensus Estimate for Stratasys’ second-quarter revenues is pegged at $148.08 million, indicating a year-over-year decrease of 7.31%. The consensus mark for the bottom line is pegged at a loss of 4 cents per share. SSYS posted non-GAAP earnings of 4 cents per share in the year-ago quarter.Its earnings beat the Zacks Consensus Estimate twice in the trailing four quarters, matched once and missed once, the average surprise ...

Core Viewpoint - The collaboration between CollPlant Biotechnologies and Stratasys aims to develop 3D printed breast implants that can regenerate natural breast tissue and degrade over time, addressing a $3 billion market opportunity in the breast implant sector [1][2][3]. Company Overview - CollPlant is focused on regenerative and aesthetic medicine, utilizing its proprietary rhCollagen technology for tissue regeneration and organ manufacturing [8]. - Stratasys is a leader in polymer 3D printing solutions, providing innovative technologies across various industries, including healthcare [6][8]. Market Opportunity - The global breast implant market is estimated at $3 billion, with breast reconstruction and augmentation being among the most common plastic surgery procedures worldwide [3]. - CollPlant's implants are designed to provide a revolutionary alternative to traditional silicone implants, which carry risks of complications [2][3]. Technological Development - The pre-clinical study will test the implants' ability to promote natural tissue growth and biodegradation, marking a significant advancement in regenerative medicine [1][2]. - Stratasys has adapted its Origin printer to produce the 200cc regenerative implants, with initial study results expected in the first half of 2025 [3][4]. Safety and Efficacy - Previous pre-clinical studies indicated positive outcomes, including well-developed connective tissue and initial biodegradation of the implants, confirming their safety profile [4].

Stratasys (SSYS) announced the launch of the latest innovation in dental 3D printing technology, DentaJet XL. This latest 3D printer aims to reduce costs and improve dental lab productivity with its Super High-Speed mode, large print tray, minimal post-processing workflow and larger resin cartridges.  The new printer is designed to work with minimal human intervention. It could reduce labor costs up to 90% with its advanced software prep, unattended printed and curing and print management features. The prin ...

Stratasys (SSYS) and Ricoh USA, Inc. have announced the commencement of a clinical study to evaluate the efficacy of 3D printed anatomical models in preoperative planning and tumor excision. This innovative approach aims to challenge the current standard of care, which relies solely on CT or MRI imaging.The study, which enrolled its first patient recently, will compare surgical outcomes between two groups, one using 3D printed models alongside traditional imaging for planning and another using imaging alone ...